Abstract
Background: Migraine is one of the most disabling diseases that continues to pose a significant societal burden. Although there are now treatment options for people with Migraine, it remains challenging to identify them as clinical features are diverse and complex, and there are no validated diagnostic or treatment prediction biomarkers. Identification is based on either diagnostic coding or the use of certain acute headache abortive treatments. However, socioeconomic disparities can contribute to under-diagnosis and under-treatment of Migraine. Thus, efforts to find biomarkers to identify individuals with Migraine and which variables could explain Migraine–related chronification and disability are warranted. We aimed to investigate the levels of migraine inducing neuropeptides; calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in peripheral blood samples as potential biomarkers of Migraine. Methods: We developed highly sensitive assays for CGRP and PACAP on the MSD S–PLEX assay platform and used them for bioanalysis of preclinical and clinical samples. Wildtype and neuropeptide challenged mice and rats were profiled using the developed assay. To follow-up, plasma from Control and people with Migraine from commercial sources were initially profiled. Subsequently, we profiled additional plasma samples from people with Migraine (during and after a headache attack), and Controls. Both MSD S–PLEX assays were transferred to Celerion where they were validated for analysis of clinical samples. Results: Using the highly sensitive PACAP assay we measured endogenous circulating levels of PACAP38 as well as administered PACAP38 in mouse and rat plasma. Additionally, using the highly sensitive CGRP assay we measured endogenous circulating levels of CGRP as well as administered CGRP in mouse and rat plasma. Furthermore, in the initial human samples, circulating CGRP and PACAP levels were not significantly different in Controls compared to people with Migraine. However, ≥50% Migraineurs showed increased circulating CGRP and PACAP levels during their attack period compared to post attack. Overall, people with Migraine showed a 3–396% increase in one or both neuropeptides during their attack period compared to post attack. Circulating plasma CGRP, and PACAP levels in Control subjects were consistent with previously measured levels. Conclusion: Our highly sensitive PACAP and CGRP assays were successful in measuring endogenous circulating levels of PACAP38 and CGRP in mouse and rat plasma. Our highly sensitive PACAP and CGRP assays were qualified for measurement of human CGRP and PACAP in Control and Migraine samples. Plasma CGRP and PACAP levels are elevated in Migraineurs during an attack period, and the increased plasma neuropeptide levels during an attack may help the differentiation of Migraineurs from Non-Migraineurs, or amongst people with Migraines to help identify the best treatment for each patient.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by H.Lundbeck A/S
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Individual control and disease-state human plasma were acquired from Cureline (USA). Cureline coordinated the prospective sample collection under institutional review board (IRB) ethical approval and with informed donor consent (IRB protocol CU-606-4797). The samples include: 1) Patient screening and selection according to the specified criteria. 2) Specimen collection and preparation according to the protocol. The samples were deidentified (Pseudonymized) under Cureline SOP CTBO.003 titled: Biospecimen deidentification, labeling and tracking, issued June 22, 2010, revised March 22, 2012.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos